Access
To read this story in full you will need to login or make a payment (see right).
Between Bedside and Bench
Nature Medicine 14, 918 - 919 (2008)
doi:10.1038/nm0908-918
Counteracting clotting in sepsis
Mark L. Kahn1
Abstract
The complexity of factors that regulate bleeding and coagulation has long confounded researchers. Andrew Wei and Shaun Jackson help clear the air by examining clinical findings pointing to a mechanistic basis for a common bleeding disorder, immune thrombocytopenic purpura. Mark Kahn tackles two research studies that could lead to improved therapies for a coagulation syndrome that hits people with severe sepsis.
Acute bacterial infection leading to sepsis affects over half a million individuals annually in the United States. Available therapies have been primarily supportive, and mortality rates still hover at 30–50%1.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
PAR1 signaling: more good than harm?Nature Medicine News and Views (01 Mar 2003)
Preventing kidney cell suicideNature Medicine News and Views (01 Nov 2007)
